Search

Search Constraints

You searched for: Author/Creator Hayama, Korenobu

Search Results

1. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema. Issue 6 (19th February 2018)

2. Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Issue 11 (30th August 2022)

3. Clinical importance of muscle volume in lenvatinib treatment for hepatocellular carcinoma: Analysis adjusted with inverse probability weighting. Issue 7 (29th November 2020)

4. Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study. Issue 1 (4th October 2022)

5. Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. (March 2021)

6. Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study. Issue 7 (16th June 2022)

7. Evaluation of 8‐week glecaprevir/pibrentasvir treatment in direct‐acting antiviral‐naïve noncirrhotic HCV genotype 1 and 2infected patients in a real‐world setting in Japan. Issue 11 (9th August 2019)

8. Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib. (1st March 2020)

9. Platelet–lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. Issue 2 (10th April 2020)

10. Platelet–lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis. Issue 2 (February 2021)